



## Technology Commercialization Opportunity

**CAMM** (CHEMICAL ASSAY TO VERIFY THE QUANTITY AND QUALITY OF MALARIA MEDICATIONS)

---

### Inventor(s):

Scott Williams, PhD., Rochester Institute of Technology

Daniel Heglund, PhD., South Dakota School of Mines and Technology

Neal Hodges II, South Dakota School of Mines and Technology

### Executive Summary:

CAMM is a colorimetric test that indicates the presence and dose of multiple malaria medications. It is simple to use, fast (minutes) and low cost (cents per test).

### Technology Description:

*Plasmodium falciparum* (malaria) infects between 200 and 500 million people per year worldwide. Nearly one million deaths per year occur, mostly in children under five. Fortunately, there is an effective therapy that is successful at treating the disease. Unfortunately, there are up to 70% counterfeit medications delivered to patient. The counterfeit manufacturers duplicate the pills to exacting color, shape, size, demarcation, blister packaging, etc. There are many other common counterfeits that need to have simple means to establish their authenticity. In western European countries consumers spent \$14 billion (USD) on counterfeit medications. Worldwide, counterfeit medications sold are worth \$75 billion (USD). The illicitly-sourced drugs include erectile dysfunction, weight loss, influenza and many more. Thus, there is an immediate need to develop technologies and methods for authenticating malaria and other counterfeit medications.

This invention relates to methods for authenticating medications and/or quantifying the active ingredients for malaria medications. Our testing methods have many advantages over existing technology. For example, our testing methods provide unmistakably clear results that can be implemented and interpreted without special training, anywhere in the world. Further, our testing methods offer both quantitative and qualitative results. The methods yield different colors where the actual color indicates the presence of the active ingredient, and the intensity of the color indicates the concentration of the active ingredient. The testing methods are very inexpensive to produce, manufacture, and employ. They are simple chemical test that requires no power, batteries, or equipment of any sort.

**Keywords:** Drug Quality Assurance, Artemisinin, Counterfeit Medication and Malaria Medication

### Technology Readiness:

Chemical testing methods have been developed for all four (4) of the Artemisinin class medications. We have completed limited testing of the chemical testing kits, and these kits are ready for an Alpha Version Trial.


Idea	Concept	Prototype	Alpha Version	Beta Version	Released
------	---------	-----------	---------------	--------------	----------

### Intellectual Property (IP):

This technology is the subject of a pending U.S. patent application.

### Applications:

Our method employs colorimetric chemical reaction for examining both the quality and quantity of active sesquiterpene lactone ingredients in antimalarial medications, including artemisinin, artesunate, artemether, and dihydroartemisinin. We employ a reagent for reacting with the medication in a solution-based reaction system. The medication can be in any form, e.g., injectable liquid, orally administered liquid, gel cap, pill, etc. Our novel reagent system is intended to react with sesquiterpene lactone derivatives, which are commonly an active ingredient in antimalarial medications. We discovered that a highly specific reaction occurs between our invented reagent and malaria medication derivatives resulting in unmistakable color change in both hue and intensity. Thus, the present invention is designed to provide a negative result (i.e., no color change) to counterfeit medicines. These counterfeits can be any chemical agent that has a physical appearance similar to the active malaria drug, but has no pharmaceutical activity toward the disease. Counterfeit agent examples include, but are not limited to, aspirin, acetaminophen, NSAIDs, vitamins, starch, cellulose, and other inert powdered agents.



**Target**

### Customers:

- Non-Government Organizations
- Pharmaceutical Companies
- Government Institutions
- Medical Pharmacies

### Opportunity:

RIT's Intellectual Property Management Office (IPMO) is interested in working with those parties who are qualified and interested in the commercialization of this CAMM technology. Arrangement types include licensing the application to existing organizations or new organizations that have expertise in the field or related fields. The inventors of the technology are available to work with licensees.

### Contact:

Those interested in learning more about this opportunity should contact:

**Mr. William E. Bond**, Director of Intellectual Property Management at RIT (585) 475-2986

[bill.bond@rit.edu](mailto:bill.bond@rit.edu)

Please refer to ID 2014-008